Invitation to Presentation of Cantargia’s Year-End Report 2024
LUND, SE / ACCESSWIRE / February 13, 2025 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) invites investors, analysts and the press to a presentation of the interim October - December and Year-End report of 2024 at 3 pm (CET) on February 21, 2025. The report will be published at 07:00 am (CET) on the same day.
In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on February 21, at 3:00 pm (CET), where Cantargia 's Interim CEO, Damian Marron, and CFO, Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session.
If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast: https://cantargia.events.inderes.com/q4-report-2024
If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference: https://conference.inderes.com/teleconference/?id=5006304
The webcast will also be available on demand on Cantargia 's corporate website: www.cantargia.com
For further information, please contact
Damian Marron, Interim CEO
Telephone: +46 (0)46-275 62 60
E-mail: damian.marron@cantargia.com
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia 's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia 's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com .
Attachments
Invitation to presentation of Cantargia 's Year-End report 2024
SOURCE: Cantargia
View the original press release on ACCESS Newswire
© 2025 ACCESS Newswire. All Rights Reserved.
